Reviparin sodium

(Redirected from Reviparin)
Jump to navigation Jump to search
Reviparin sodium
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Reviparin sodium


Most recent articles on Reviparin sodium

Most cited articles on Reviparin sodium

Review articles on Reviparin sodium

Articles on Reviparin sodium in N Eng J Med, Lancet, BMJ


Powerpoint slides on Reviparin sodium

Images of Reviparin sodium

Photos of Reviparin sodium

Podcasts & MP3s on Reviparin sodium

Videos on Reviparin sodium

Evidence Based Medicine

Cochrane Collaboration on Reviparin sodium

Bandolier on Reviparin sodium

TRIP on Reviparin sodium

Clinical Trials

Ongoing Trials on Reviparin sodium at Clinical

Trial results on Reviparin sodium

Clinical Trials on Reviparin sodium at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Reviparin sodium

NICE Guidance on Reviparin sodium


FDA on Reviparin sodium

CDC on Reviparin sodium


Books on Reviparin sodium


Reviparin sodium in the news

Be alerted to news on Reviparin sodium

News trends on Reviparin sodium


Blogs on Reviparin sodium


Definitions of Reviparin sodium

Patient Resources / Community

Patient resources on Reviparin sodium

Discussion groups on Reviparin sodium

Patient Handouts on Reviparin sodium

Directions to Hospitals Treating Reviparin sodium

Risk calculators and risk factors for Reviparin sodium

Healthcare Provider Resources

Symptoms of Reviparin sodium

Causes & Risk Factors for Reviparin sodium

Diagnostic studies for Reviparin sodium

Treatment of Reviparin sodium

Continuing Medical Education (CME)

CME Programs on Reviparin sodium


Reviparin sodium en Espanol

Reviparin sodium en Francais


Reviparin sodium in the Marketplace

Patents on Reviparin sodium

Experimental / Informatics

List of terms related to Reviparin sodium

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins.


Reviparin is a low molecular weight heparin (LMWH) obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.


  • Prophylaxis of deep vein thrombosis (DVT)
  • Prophylaxis of perioperative thromboembolism[1][2]
  • Treatment of DVT with or without pulmonary embolism (PE)[3]
  • Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)[4][5]


  1. Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thromb. Res. 81 (2 Suppl): S39–45. PMID 8822126. |access-date= requires |url= (help)
  2. Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMID 10549720. |access-date= requires |url= (help)
  3. Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use". J Indian Med Assoc. 102 (10): 589–90, 592. PMID 15887830. |access-date= requires |url= (help)
  4. Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty". Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60. PMID 8180331. |access-date= requires |url= (help)
  5. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation". J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. PMID 8917255. Retrieved 2014-09-18.

External links

  • reviparin at the US National Library of Medicine Medical Subject Headings (MeSH)
  • Yusuf S, Mehta SR, Xie C; et al. (2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation". JAMA. 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMID 15671427.